Literature DB >> 8677507

[The remineralization of the vertebral metastases of breast carcinoma after radiotherapy].

I Wachenfeld1, G Sanner, H D Böttcher, J Kollath.   

Abstract

BACKGROUND: The early detection of effects caused by radiotherapy on bone mineralisation has influence on clinical treatment. Usually the follow-up is done by conventional X-rays, presenting a loss of calcification of at least 30%. Quantitative CT-measurements are much more sensitive. PATIENTS AND METHODS: In a prospective study we evaluated the CT-scans of 14 patients with multiple vertebral metastases of mamma carcinoma. Our patients underwent SEQCT (one 10 mm slice in each affected vertebral body, 80 kV, 250 mAs) before and immediately after radiation therapy (total dose 30 Gy to 36 Gy) followed by further examinations 6 weeks and 3 months later.
RESULTS: While there is no significant change in increased BMD (bone mineral density) of osteosclerotic and decreased BMD of osteolytic metastases just after therapy, the following examinations present an increase of BMD in osteolytic metastases 6 weeks after therapy more distinct 3 months after. Osteosclerotic metastases show a decline in bone density. In mixed metastases is no significant change while normal bone lying in the irradiation field demineralizes. Additive chemotherapy is very important especially for mineralisation of lytic metastases. Referring to mixed metastasis in one vertebral body we suggest a separate evaluation of the left and right side.
CONCLUSION: Mineralizing effects of radiation therapy depend on the characteristics of the metastases. Supported by QCT histopathological change can be documented and exactly demonstrated to the clinician.

Entities:  

Mesh:

Year:  1996        PMID: 8677507

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  6 in total

1.  Magnetic resonance-guided focused ultrasound for the treatment of painful bone metastases: role of apparent diffusion coefficient (ADC) and dynamic contrast enhanced (DCE) MRI in the assessment of clinical outcome.

Authors:  Michele Anzidei; Alessandro Napoli; Beatrice Sacconi; Fabrizio Boni; Vincenzo Noce; Michele Di Martino; Luca Saba; Carlo Catalano
Journal:  Radiol Med       Date:  2016-08-27       Impact factor: 3.469

2.  Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy.

Authors:  Ricarda Merten; Markus Hecht; Marlen Haderlein; Luitpold Distel; Rainer Fietkau; Lucie Heinzerling; Sabine Semrau
Journal:  Strahlenther Onkol       Date:  2014-06-26       Impact factor: 3.621

3.  Local response and pathologic fractures following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy for spinal metastases - a randomized controlled trial.

Authors:  Tanja Sprave; Vivek Verma; Robert Förster; Ingmar Schlampp; Katharina Hees; Thomas Bruckner; Tilman Bostel; Rami Ateyah El Shafie; Thomas Welzel; Nils Henrik Nicolay; Jürgen Debus; Harald Rief
Journal:  BMC Cancer       Date:  2018-08-31       Impact factor: 4.430

4.  Bone Density Changes Following Radiotherapy to Vertebral Metastases.

Authors:  Garrett L Jensen; Ravi Gaddipati; Kendall P Hammonds; Andrew Morrow; Gregory P Swanson
Journal:  Cureus       Date:  2021-06-03

5.  The influence of fractionated radiotherapy on the stability of spinal bone metastases: a retrospective analysis from 1047 cases.

Authors:  Tanja Sprave; Katharina Hees; Thomas Bruckner; Robert Foerster; Tilman Bostel; Ingmar Schlampp; Rami El Shafie; Nils Henrik Nicolay; Juergen Debus; Harald Rief
Journal:  Radiat Oncol       Date:  2018-07-24       Impact factor: 3.481

6.  Bone density and pain response following intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for vertebral metastases - secondary results of a randomized trial.

Authors:  Tanja Sprave; Vivek Verma; Robert Förster; Ingmar Schlampp; Katharina Hees; Thomas Bruckner; Tilman Bostel; Rami Ateyah El Shafie; Thomas Welzel; Nils Henrik Nicolay; Jürgen Debus; Harald Rief
Journal:  Radiat Oncol       Date:  2018-10-30       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.